What You Should Know:
– ARTBIO, Inc., a leader in developing targeted alpha radioligand therapies (ARTs) for cancer, and Nucleus RadioPharma Inc., a pioneer in radiopharmaceutical development and manufacturing, announced today a strategic collaboration to propel ARTBIO’s clinical trials forward.
Nucleus to Manufacture ARTBIO’s Lead Therapy Candidate
This agreement signifies a significant step for ARTBIO. Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials. The key focus will be on AB001, ARTBIO’s lead program targeting prostate cancer. ARTBIO’s proprietary AlphaDirectTM technology will be utilized for the isolation of 212Pb during this manufacturing process.
Nucleus Facility to Serve Northern and Midwestern US Patients
The agreement facilitates the production and supply of ARTs from Nucleus’ state-of-the-art facility in Rochester, Minnesota. This strategic location will ensure efficient treatment access for patients residing in the Northern and Midwestern regions of the United States.
AlphaDirectTM: A Pioneering Approach to 212Pb Isolation
ARTBIO’s AlphaDirectTM technology represents a groundbreaking advancement in radiopharmaceutical production. This first-of-its-kind system offers a reliable and efficient method for isolating highly pure 212Pb, a radioisotope with promising therapeutic potential. 212Pb’s unique properties, particularly its short half-life, make it an attractive candidate for targeted alpha radioligand therapy. Early studies suggest 212Pb-based radiopharmaceuticals hold significant promise in addressing unmet needs in cancer treatment.
“As we continue building our distributed manufacturing capabilities in the U.S. and globally, selecting partners who share our patient-centric vision is critical,” said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO. “The Nucleus team shares our passion to make targeted radiopharmaceutical therapies accessible, and together, we commit to bringing a new class of alpha radioligand therapies to hospitals across greater Minnesota and beyond.
